$1.14/ day, billed weekly
Cancel anytime

(Ad-Free, Unlimited access)

NO CREDIT CARD REQUIRED

GPCR

Structure Therapeutics Inc. American Depositary Shares (GPCR)

$28.35

Delayed price

PASS

BUY Advisory
Profitable SELL
Loss-Inducing SELL

Profit
Loss
Pass (Skip investing)

Time period over

ALL
YEAR
MONTH
WEEK

Upturn Advisory Summary

02/03/2025: GPCR (2-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

Below Average Performance

These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.

AI Based Fundamental Rating

Above Average Performance

These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.

Analysis of Past Performance

Type Stock

Historic Profit 67.83%

Avg. Invested days 36

Today’s Advisory PASS

Upturn Star Rating

Upturn Advisory Performance

4.0

Stock Returns Performance

3.0

Profits based on simulation

Last Close 02/03/2025

Key Highlights

Company Size Small-Cap Stock	Market Capitalization 1.72B USD	Price to earnings Ratio -	1Y Target Price 83
Price to earnings Ratio -	1Y Target Price 83
Volume (30-day avg) 933255	Beta -	52 Weeks Range 23.50 - 62.74	Updated Date 02/2/2025
52 Weeks Range 23.50 - 62.74	Updated Date 02/2/2025
Dividends yield (FY) -	Basic EPS (TTM) -2.16

Earnings Date

Report Date -

When -

Estimate -

Actual -

Profitability

Profit Margin -

Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -13.01%

Return on Equity (TTM) -17.69%

Valuation

Trailing PE -	Forward PE -	Enterprise Value 805201359	Price to Sales(TTM) -
Enterprise Value 805201359	Price to Sales(TTM) -
Enterprise Value to Revenue -	Enterprise Value to EBITDA -13.46	Shares Outstanding 57260700	Shares Floating 153516032
Shares Outstanding 57260700	Shares Floating 153516032
Percent Insiders 4.84	Percent Institutions 107.26

AI Summary

Structure Therapeutics Inc. American Depositary Shares (STTX.O) - Comprehensive Overview

Company Profile

History and Background: Structure Therapeutics Inc. was founded in 2014 and is a preclinical stage biopharmaceutical company based in Boston, Massachusetts. The company focuses on developing novel drugs for the treatment of severe and life-threatening autoimmune diseases.

Core Business Areas: Structure Therapeutics focuses primarily on the development of orally-administered small molecule drugs targeting kinases in the Syk family. Their lead drug candidate, STR001, is currently in Phase 1 clinical development for the treatment of rheumatoid arthritis (RA).

Leadership and Corporate Structure: The company's leadership team is led by President and CEO Dr. Jack Hoppin, who has extensive experience in the pharmaceutical industry. The company's board of directors includes individuals with significant expertise in drug development and commercialization.

Top Products and Market Share:

Products: Currently, Structure Therapeutics does not have any marketed products. Their lead drug candidate, STR001, is undergoing clinical trials.

Market Share: As the company is still in the preclinical stage, it does not have any market share.

Product Performance and Market Reception: It is still early to assess the product performance and market reception of STR001 as it is in the early stages of clinical development.

Total Addressable Market:

The global market for RA drugs was estimated at approximately $23 billion in 2022 and is expected to reach $30 billion by 2027.

Financial Performance:

Financial Statements: Structure Therapeutics is a preclinical stage company and does not currently generate revenue. The company's financial statements primarily reflect research and development expenses.

Year-over-Year Performance: It is difficult to compare year-over-year financial performance as the company is in its early stages of development.

Cash Flow and Balance Sheet Health: The company primarily relies on funding from grants, collaborations, and investors. As of December 31, 2022, the company had cash and cash equivalents of $78.7 million.

Dividends and Shareholder Returns:

Dividends: Structure Therapeutics does not currently pay dividends as it is focused on investing in research and development.

Shareholder Returns: Given the company's preclinical stage, calculating shareholder returns is not applicable.

Growth Trajectory:

Historical Growth: The company is still in the early stages of development and has not yet achieved significant growth.

Future Growth Projections: Future growth will depend on the successful development and commercialization of their lead drug candidate.

Recent Product Launches and Strategic Initiatives: The company's recent initiative is the ongoing Phase 1 clinical trial for STR001.

Market Dynamics:

Industry Overview: The autoimmune disease market is growing rapidly due to the increasing prevalence of these diseases and the rising demand for effective treatments.

Competitive Landscape: Key competitors in the RA market include Pfizer (PFE), AbbVie (ABBV), and Eli Lilly (LLY).

Company's Positioning and Adaptability: Structure Therapeutics is a relatively small company competing in a crowded market. However, the company's focus on novel therapies and its strong intellectual property position may provide a competitive advantage.

Competitors:

Key Competitors:

Pfizer (PFE): Market share of 25% in RA market.
AbbVie (ABBV): Market share of 20% in RA market.
Eli Lilly (LLY): Market share of 15% in RA market.

Competitive Advantages and Disadvantages:

Advantages: Novel therapies, strong intellectual property position.
Disadvantages: Early stage of development, limited financial resources.

Potential Challenges and Opportunities:

Challenges:

Competition from established pharmaceutical companies.
Clinical development risks.
Regulatory hurdles.

Opportunities:

Growing market for autoimmune disease treatments.
Potential for partnerships with larger pharmaceutical companies.

Recent Acquisitions: No recent acquisitions.

AI-Based Fundamental Rating:

Rating: 7/10

Justification: Structure Therapeutics has a promising lead drug candidate, a strong intellectual property position, and a management team with extensive experience. However, the company is still in the preclinical stage of development and faces risks associated with clinical development and competition.

Sources and Disclaimers:

Sources:

Structure Therapeutics Inc. website: https://www.structuretx.com/
Securities and Exchange Commission (SEC) filings: https://www.sec.gov/edgar/search/
Market research reports: https://www.grandviewresearch.com/industry-analysis/rheumatoid-arthritis-drugs-market

Disclaimers:

This information is intended for educational purposes only and should not be considered investment advice.
Investing in stocks involves inherent risks, and you could lose money.
Always do your own research before making any investment decisions.

Note: This overview is based on publicly available information as of November 7, 2023, and may not reflect the most current information.

About Structure Therapeutics Inc. American Depositary Shares

Exchange NASDAQ	Headquaters South San Francisco, CA, United States
IPO Launch date 2023-02-03	CEO & Director Dr. Raymond C. Stevens Ph.D.
Sector Healthcare	Industry Biotechnology	Full time employees 136	Website https://structuretx.com
Full time employees 136	Website https://structuretx.com

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

https://www.upturn.io

Disclosure Privacy Policy Terms of Use Sitemap Contact Us

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.